Insights From ASCO 2025 Guide Pharmacy Practice in Solid Tumors and Hematologic Cancers
Pharmacy Times
JULY 16, 2025
Further, the incidence, severity, and kinetics of cytokine release syndrome (CRS) and immune effector cell–associated neurotoxicity syndrome with CD20 × CD3 TCEs may vary depending on the B-cell lymphoma subtype and the combination partners used, which is a notable consideration for oncology pharmacists when operationalizing these therapies.
Let's personalize your content